Table 2 Characteristics and outcome variables in treated patients with NSVN

MRC sum score

a) Median (Q1, Q3) baseline/ follow-up

29 (28, 30)

28 (26, 29)

30 (28.5, 30)

28 (24.5, 30)/28 (27, 30)

b) Change at follow-up

 Improved (n)

0/13

3/10

0/9

1/5

 Unchanged (n)

11/13

4/10

9/9

4/5

 Worse (n)

2/13

3/10

0/9

0/5

Sensory symptoms

(Change at follow-up)

 Improved (n)

2/13

2/10

2/9

3/5

 Unchanged (n)

8/13

7/10

5/9

2/5

 Worse (n)

3/13

1/10

2/9

0/5

Pain

(Change at follow-up)

 Improved (n)

2/13

0/10

3/9

0/5

 Unchanged (n)

7/13

10/10

5/9

5/5

 Worse (n)

4/13

0/10

1/9

0/5

Tibial CMAP-amplitude

Median (Q1, Q3) baseline/ follow-up

0.4 (0.05, 1.05)/0.5 (0.0, 0.9)

0.4 (0.075, 1)/0.25 (0.2, 0.6)

1.3 (0.45, 3.8)/0.6 (0.4, 1.4)

1.8 (0.3, 14.9)/3.7 (0.15, 14.25)

EMG-spontaneous activity at baseline

Not existent (n)

5/13

2/10

5/9

1/5

Mild (n)

5/13

4/10

2/9

2/5

Moderate to severe (n)

3/13

4/10

2/9

2/5